

Lipidor adds capital through sale of shares

STOCKHOLM, Sweden, 6th March 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that 100 Emollivet shares, corresponding to approximately SEK 0.7 million, have been divested to Cerbios-Pharma SA.

As previously announced, Lipidor is carrying out a step-by-step divestment of its holding in the animal company Emollivet AB. A total of 100 shares in Emollivet have been sold today to Cerbios-Pharma SA at a price per share of SEK 7,290 and through the transaction Lipidor will receive approximately SEK 0.7 million.

In December, Lipidor announced that a loan of approximately SEK 0.6 million had been raised from Cerbios-Pharma, and that repayment of the loan will be made with 89 Emollivet shares. This is now imminent and shortly the loan will be converted into shares. Following today's transaction and the imminent loan-to-share conversion, Lipidor still owns 64 shares in Emollivet, representing 2% of the company. Parts or all of the remaining holding may also be divested in order to strengthen Lipidor's position in the short term.

"We can once again say that Lipidor's largest shareholder Cerbios-Pharma has stepped forward to take a great responsibility for moving Lipidor's business forward, towards a planned financing and to the primary goal of conducting a clinical Phase III study for our psoriasis candidate", says Ola Holmlund, CEO of Lipidor.

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

About Lipidor AB

Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor's priority project is AKP02G2, which focusses on psoriasis.

This information is information that Lipidor AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-06 12:31 CET.

Attachments

[Lipidor adds capital through sale of shares](#)